Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of traditional Chinese medicine composition in preparation of medicine for preventing/treating macular degeneration disease

A technology of macular degeneration and composition, which is applied in the direction of drug combination, sensory disease, cardiovascular system disease, etc., can solve the problems of patient's inconvenience, abnormal ascending and descending, etc., and achieve the effect of easy taking, simple operation and good clinical curative effect

Pending Publication Date: 2021-11-16
王保安
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Its dialectical treatment mainly includes senile body failure, liver and kidney deficiency; hyperactivity of liver yang, heart fire and blood; liver and spleen imbalance, abnormal ascending and descending; although acupuncture and moxibustion combined with oral Chinese medicine have certain curative effects, long-term treatment will bring inconvenience to patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of traditional Chinese medicine composition in preparation of medicine for preventing/treating macular degeneration disease
  • Application of traditional Chinese medicine composition in preparation of medicine for preventing/treating macular degeneration disease
  • Application of traditional Chinese medicine composition in preparation of medicine for preventing/treating macular degeneration disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0048] Embodiment 1 Observation of the clinical efficacy of the pharmaceutical composition of the present invention in the treatment of wet age-related macular degeneration

[0049] 1. Objects and methods

[0050] 1.1 Clinical data

[0051] From June 2013 to the present, led by Peking Union Medical College Hospital, Beijing Tongren Hospital Affiliated to Capital Medical University, Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing Hospital of the Ministry of Health, China-Japan Friendship Hospital, Tianjin Eye Hospital, participated in hemostasis, blood stasis, and eyesight Systematic evidence-based medical research has been carried out for the treatment of wet age-related macular degeneration with tablets.

[0052] 1.2 Standards of diagnosis and treatment

[0053] 1.2.1 Western medicine diagnostic criteria (based on the 7th edition of "Ophthalmology" and the 3rd edition of "Practical Ophthalmology") for patients with typical CNV confirmed by FFA,...

Embodiment 2

[0293] Example 2 Observation of the clinical efficacy of the pharmaceutical composition of the present invention in the treatment of wet age-related macular degeneration

[0294] Using the same number of people, test methods, inclusion and evaluation criteria as in Example 1, the clinical curative effects of the three groups of drugs were observed, and the results are as follows.

[0295] 1.1 Distribution of selected cases and determination of analysis data sets

[0296] Combined medication group: 99 people were enrolled, 12 people dropped out, and the dropout rate was 12.12%;

[0297] Ranibizumab group: 33 people enrolled, 4 dropped out, the dropout rate was 12.12%;

[0298] Traditional Chinese medicine group: 36 people were enrolled, 2 people dropped out, and the dropout rate was 5.56%;

[0299] Table 25 Distribution of selected cases in the three groups and determination of analysis data sets

[0300]

[0301] The drop-off rates of each group were: the combination dru...

Embodiment 3

[0385] Embodiment 3 capsules

[0386] Prescription: with embodiment 3

[0387] Preparation.

[0388] (1), mix the Scutellaria baicalensis slices with wine, stuff them thoroughly, put them in a pot, fry them dry with a slow fire, take them out, let them cool, and set aside; (2) Mix Salvia miltiorrhiza and Panax notoginseng, grind them into fine powder, and set aside;

[0389] (3) Remove the other ten herbs except Salvia miltiorrhiza and Panax notoginseng, decoct twice with water, two hours each time, combine the decoction liquid, filter, and concentrate the filtrate under reduced pressure until the temperature is 60°C and the relative density is 1.35 -1.39 thick paste, mixed with the above step (2) Chinese medicine powder, dried at 60°C, crushed into fine powder, added appropriate amount of dextrin, granulated with 85% ethanol, dried at 60°C, granulated, added 0.5% of magnesium stearate, mix well.

[0390] (4) Take the granules mixed in step (3) and put them into 1# hollow c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of a traditional Chinese medicine composition in preparation of a medicine for preventing / treating macular degeneration diseases. The traditional Chinese medicine composition is prepared from the following raw materials in percentage by weight: 9.5 to 14.5 percent of radix salviae miltiorrhizae, 9.5 to 14.5 percent of radix rehmanniae, 8.0 to 12.0 percent of herba ecliptae, 8.0 to 12.0 percent of fructus leonuri, 3.5 to 5.5 percent of radix notoginseng, 8.0 to 12.0 percent of radix paeoniae rubra, 8.0 to 12.0 percent of cortex moutan, 8.0 to 12.0 percent of fructus ligustri lucidi, 4.8 to 7.2 percent of spica prunellae, 4.8 to 7.2 percent of radix ilicis pubescentis, 3.5 to 5.5 percent of radix et rhizoma rhei and 3.5 to 5.5 percent of radix scutellariae. The traditional Chinese medicine composition disclosed by the invention is beneficial to environmental protection and has a relatively good clinical application prospect. The traditional Chinese medicine composition disclosed by the invention has the advantages of easily available raw materials, simplicity in operation, suitability for industrial production and higher application value.

Description

[0001] This application is a divisional application with an application date of September 06, 2016, an application number of 201610804919.5, and an invention title of “A Chinese medicinal composition used in the preparation of drugs for the prevention / treatment of macular degeneration”. technical field [0002] The present invention relates to traditional Chinese medicine, in particular to a traditional Chinese medicine composition, in particular to the application of a traditional Chinese medicine composition in the preparation of drugs for the prevention / treatment of macular degeneration, in particular to the application of a traditional Chinese medicine composition in the preparation of prevention / treatment of age-related macular degeneration application in disease medicine. Background technique [0003] Age-related macular degeneration (age-related macular degeneration, AMD), also known as age-related macular degeneration (senile macular degeneration, SMD), is one of the ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/804A61K39/395A61P27/02A61P9/10
CPCA61K36/185A61K36/258A61K36/28A61K36/533A61K36/536A61K36/537A61K36/539A61K36/638A61K36/65A61K36/708A61K36/71A61K36/804A61K39/39533A61P27/02A61P9/10A61K2236/331A61K2236/39A61K2236/51A61K2300/00
Inventor 王保安毛鹏
Owner 王保安
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com